Publication:
Adjuvant or salvage radiotherapy in postoperative prostate cancer

Placeholder

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Kuban, Deborah A.

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Prostate-specific antigen (PSA) screening increased the diagnosis of prostate cancer at a localized stage to be treated with a curative intent; approximately half of them undergo radical prostatectomy, and roughly one third of surgically treated patients are expected to experience a recurrence in 10 years' follow-up. Once PSA failure occurs, many develop distant metastases at a median of 8 years and afterward followed by cancer-related death at a median of 5 years. Biochemical failure risk after radical prostatectomy is mainly expected mostly in men with any of the following features: detectable postoperative PSA, positive surgical margins, extraprostatic extension of tumor (T3a), seminal vesicle invasion (T3b), and Gleason score ≥ 8. The radiotherapy in the undetectable PSA environment (<0.01 ng/mL) within 4 months after prostatectomy is termed as "adjuvant," while radiotherapy in rising PSA within any time after prostatectomy is defined as "salvage."

Source

Publisher

Springer

Subject

Oncology, Urology, Nephrology

Citation

Has Part

Source

Principles and Practice of Urooncology: Radiotherapy, Surgery and Systemic Therapy

Book Series Title

Edition

DOI

10.1007/978-3-319-56114-1_17

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details